Identifying and addressingcriticalsocial,ethical, and behavioralfactorsassociated with COVID-19testing and vaccinationamongSpanishspeakers
Project Number1U01MD017431-01
Former Number1U01AG077343-01
Contact PI/Project LeaderRHODES, SCOTT D Other PIs
Awardee OrganizationWAKE FOREST UNIVERSITY HEALTH SCIENCES
Description
Abstract Text
Summary
Latinx communities are disproportionately affected by the COVID-19 pandemic, with Spanish-speaking Latinx
communities carrying even heavier burdens of infection, hospitalization, and mortality. Major barriers to
COVID-19testing and vaccination exist, and a profound need remains to understand and address the social,ethical, and behavioral implications (SEBI) of COVID-19testing and vaccination within Latinx communities. Our
well-established community-academic partnership proposes a rigorous mixed-methods, community-based
participatory research (CBPR) study better understand the SEBI of COVID-19testing and vaccination and to
refine and test a novel and culturally congruent intervention to increase COVID-19testing and vaccination
within Spanish-speaking Latinx communities.
In Aim 1, we will conduct individual in-depth interviews with health providers and representatives from Latinx-
serving community-based organizations and focus groups with Spanish-speaking Latinx community members
to expand our understanding of the individual, interpersonal, institutional, community, and policy factors
influencing COVID-19testing and vaccination within Spanish-speaking Latinx communities. In Aim 2, we will
integrate findings from other relevant COVID-19 studies and from Aim 1 to refine a Spanish-language
intervention known as NuestraSaludSegura (Our Safe Health) designed to increase COVID-19testing and
vaccinationamongSpanish-speaking Latinx persons. NuestraSaludSegura harnesses the complementary
strengths of peer navigation and mHealth. We will also test the intervention using a longitudinal group-
randomized trial design assessing participants at: (1) baseline and (2) immediate post intervention. We
anticipate that participants in the intervention group, relative to their counterparts in the delayed -intervention
group, will demonstrate increased COVID-19testing and vaccination. In Aim 3, we will develop and
disseminate practice, research, intervention, and policy priorities and recommendations to increase COVID-19testing and vaccination, reduce COVID-19 disparities, and promote health equity in Spanish-speaking Latinx
communities by conducting an empowerment theory-based community forum.
This CBPR study will advance prevention science and practice through increased understanding of the SEBI of
COVID-19testing and vaccination and testing an innovative intervention to promote and support COVID-19testing and vaccinationamong a particularly underserved and vulnerable population – Spanish-speaking Latinx
communities in the United States.
Public Health Relevance Statement
Narrative
Latinx communities are disproportionately affected by the COVID-19 pandemic, with Spanish-speaking Latinx
communities carrying even heavier burdens of infection, hospitalization, and mortality. Major barriers to
COVID-19testing and vaccination exist, and a profound need remains to understand and address the social,ethical, and behavioral implications (SEBI) of COVID-19testing and vaccination within Latinx communities. Our
community-academic partnership proposes a rigorous mixed-methods, community-based participatory
research study to better understand the SEBI of COVID-19testing and vaccination and to refine and test a
novel and culturally congruent intervention that integrates two evidenced-based strategies – peer navigation
and mHealth – to increase COVID-19testing and vaccination within Spanish-speaking Latinx communities.
National Institute on Minority Health and Health Disparities
CFDA Code
310
DUNS Number
937727907
UEI
SN7KD2UK7GC5
Project Start Date
01-January-2022
Project End Date
30-November-2023
Budget Start Date
01-January-2022
Budget End Date
30-November-2022
Project Funding Information for 2022
Total Funding
$570,920
Direct Costs
$418,808
Indirect Costs
$152,112
Year
Funding IC
FY Total Cost by IC
2022
NIH Office of the Director
$570,920
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U01MD017431-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U01MD017431-01
Patents
No Patents information available for 1U01MD017431-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U01MD017431-01
Clinical Studies
No Clinical Studies information available for 1U01MD017431-01
News and More
Related News Releases
No news release information available for 1U01MD017431-01
History
No Historical information available for 1U01MD017431-01
Similar Projects
No Similar Projects information available for 1U01MD017431-01